399 A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer
399 A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer